HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Webinars
    • Conferences
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists

Johnson & Johnson’s Drug Combination Improves Progression-Free Survival in Lung Cancer Trial Against AstraZeneca’s Therapy

The Mariposa study showed that a combination of two Johnson & Johnson (J&J) drugs, Rybrevant, and lazertinib, was successful in improving progression-free survival in a common type of metastatic lung tumor, compared to AstraZeneca's Tagrisso. These interim results have been closely […]

more info 09/29/2023View Related Articles
Bookmark and Share

Unveiling the NHS Data Landscape: First Comprehensive Mapping for Improved Transparency and Efficiency

Researchers from the Institute of Global Health Innovation at Imperial College London have mapped and evaluated all electronic data flows in the NHS for the first time, revealing a complex landscape with tens of thousands of data transactions. This important research, published in The Lancet Digital […]

more info 09/28/2023View Related Articles
Bookmark and Share

Risk of Long Covid Increases with Each COVID-19 Reinfection, Indicates Study

The coronavirus pandemic has prompted questions about reinfection and the risk of developing "long Covid" characterized by fatigue, brain fog, musculoskeletal pain, shortness of breath, gastrointestinal disorders, and dysautonomia, among other issues. Research led by Ziyad Al-Aly, chief of research […]

more info 09/21/2023View Related Articles
Bookmark and Share

Cognitive Ability Tied to COVID-19 Vaccination Rates

The study published in the Journal of Health Economics investigated a link between an individual's cognitive ability and their decision to receive the COVID-19 vaccination. The researchers found that people with higher cognitive abilities were likely to get vaccinated faster than those with lower […]

more info 09/13/2023View Related Articles
Bookmark and Share

Updates to Keep an Eye on

The FDA has fast-tracked approval of Pfizer's Elfrexfio drug for hard-to-treat multiple myeloma, offering new hope to patients. State and local governments are currently wrestling with how best to distribute funding from opioid crisis-related settlements as public health groups question the […]

more info 08/16/2023View Related Articles
Bookmark and Share

Act4Biosimilars Advocacy Group Strives to Boost Global Adoption of Biosimilars by 2030

Act4Biosimilars, a global biosimilar advocacy initiative, aims to increase global adoption of biosimilars by at least 30 percentage points in over 30 countries by 2030. Here's what you need to know:  Regulatory and policy hurdles and varied market dynamics cause disparities in biosimilar […]

more info 08/10/2023View Related Articles
Bookmark and Share

Millennials and Gen Z More Likely to Buy from Brands Promoting Healthy Lifestyle

According to a DirecTV Advertising report, Millennials and Gen Z are more inclined towards brands promoting a healthy lifestyle than Baby Boomers. Approximately 60% of Millennials would likely buy from these brands, compared to 50% of Gen Xers, 39% of Gen Zers, and 38% of Boomers. Over 40% of […]

more info 07/28/2023View Related Articles
Bookmark and Share

Infectious Disease Market Projected to Grow by 5.7% Led by Pfizer, Gilead Sciences, and GSK

According to a report by GlobalData, the infectious disease market is projected to grow actively from 2023 to 2029 and sales are predicted to reach $150 billion by 2029. It is expected that Pfizer, Gilead Sciences, and GlaxoSmithKline (GSK) will be the major players in the market. What You Need […]

more info 07/28/2023View Related Articles
Bookmark and Share

Groundbreaking Alliance: RetinAI Medical AG Joins Forces with Retina Consultants of America!

RetinAI Medical AG (RetinAI) and Retina Consultants of America (RCA) are partnering to advance artificial intelligence (AI) applications in the analysis of clinical and imaging data in ophthalmology. The partnership leverages RetinAI's digital health technologies and RCA's large patient data network […]

more info 07/26/2023View Related Articles
Bookmark and Share

Medlinker’s AI Doctors Almost Match Human Physicians in Groundbreaking Live Test

Medlinker, a Chinese digital healthcare company, hosted a live comparison of its AI doctors, MedGPT, and human doctors in Chengdu, with MedGPT scoring 7.2 out of 10, compared to an average of 7.5 for human doctors, based on an assessment by seven notable physicians. Furthermore, the recommendations […]

more info 07/24/2023View Related Articles
Bookmark and Share

ITIF Report: Global Drug Price Controls Restrict Pharmaceutical Research and Development

The Information Technology and Innovation Foundation (ITIF) study reports that drug price controls in non-US Organization for Economic Cooperation and Development (OECD) nations inhibit biopharmaceutical R&D by over $56 billion annually, foregoing the creation of around 25 new drugs yearly. If […]

more info 07/18/2023View Related Articles
Bookmark and Share

BridgeBio’s Experimental Results Boosts Company Shares by 65%

BridgeBio Pharma Inc's experimental drug, acoramidis, for rare heart disease, has shown significant improvement in a late-stage study, boosting its market shares by 65%. Acoramidis functions to prevent heart failure by addressing anomalous protein deposits in the heart. It is expected to compete […]

more info 07/17/2023View Related Articles
Bookmark and Share

Insights into the Global Real World Evidence Solutions Market 2023-2030

10 Things You Need to Know:  The projection shows the market size growing from $16.3 billion in 2023 to $36.24 billion in 2030, with a CAGR of 12.3%. IQVIA Inc., UnitedHealth Group, IBM, and Cognizant are currently the major players to pay attention to in the market. Advanced analytics […]

more info 07/12/2023View Related Articles
Bookmark and Share

Price Break: Cigna Welcomes Trio of Discounted Biosimilars to Preferred Drug Roster

What You Need to Know:  Cigna Group's unit, Express Scripts, is adding three biosimilar versions of AbbVie's arthritis treatment Humira to its preferred drugs list. Reuters explains that “The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' […]

more info 07/11/2023View Related Articles
Bookmark and Share

Geisinger Program Slows Spending Growth on Biologics

A comparative effectiveness program launched by Geisinger Health has reportedly slowed the rapid increase in biologic spending, according to an HFMA report. According to the report, Geisinger Health Plan's spending on biologics accounted for about 35.9 percent of its total drug spending in 2018, […]

more info 04/19/2019View Related Articles
Bookmark and Share

2015 Comparative Effectiveness Research Infographic

Now in its fifth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Infographic available for download here. (Source: National Pharmaceutical […]

more info 03/11/2016View Related Articles
Bookmark and Share

The Myth of Average: Infographic for Patients

Understanding which health care treatments or preventive care will work best for you is important. This infographic for patients is available for download here. (Source: National Pharmaceutical Council) […]

more info 03/11/2016View Related Articles
Bookmark and Share

The Myth of Average (Health Professionals) Infographic

Understanding which health care treatments or preventative care will work best for you is important. Infographic available for download here. (Source: National Pharmaceutical Council) […]

more info 03/11/2016View Related Articles
Bookmark and Share

2014 Comparative Effectiveness Research and the Environment for Health Care Decision-Making Infographic

Now in its fourth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Take a look at this infographic. (Source: National Pharmaceutical Council) […]

more info 03/11/2016View Related Articles
Bookmark and Share

National Pharmaceutical Council. 2014 Comparative Effectiveness Research and Environment Health Care Decision-Making Infographic.

NPC Infographic

Or download the infographic PDF file here. […]

more info 03/09/2015View Related Articles
Bookmark and Share

Health Care Decision Makers’ Use of Comparative Effectiveness Research: Report from a Series of Focus Groups

more info 12/04/2013View Related Articles
Bookmark and Share

Challenging a Sacred Cow: The Top-Down Approach to Comparative Effectiveness

Blog posting by Nick Emptage, healthycriticism.com, describing CER goals, considerations (statistical sig, measured effect meaning, whether comparisons are valid). […]

more info 10/24/2013View Related Articles
Bookmark and Share

Demystifying Comparative Effectiveness Research: A Case Study Learning Guide

more info 10/24/2013View Related Articles
Bookmark and Share

Infographic: Is Comparative Effectiveness Research Meeting Market Demand?

Since January 2010, HTA organizations across the globe have issued nearly 1,000 CE reports. Yet just 5% of this U.S.-based research and 9% of research outside the U.S. address four high-burden conditions: non-small cell lung cancer, rheumatoid arthritis, multiple sclerosis and hepatitis C. […]

more info 10/24/2013View Related Articles
Bookmark and Share

Methods in Comparative Effectiveness Research

more info 10/24/2013View Related Articles
Bookmark and Share

Communicating About Comparative Effectiveness Research: A Health Affairs Symposium on the Issues

more info 10/24/2013View Related Articles
Bookmark and Share

Opportunities and Challenges for Comparative Effectiveness Pragmatic Clinical Trials in Europe, PPT

Presentation at ISPOR Europe, Nov. 2011, by Marc L. Berger, M.D., Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA […]

more info 10/24/2013View Related Articles
Bookmark and Share

Personalized Medicine and Companion Diagnostics in Oncology: Challenges and Solutions, PPT

Presentation at ISPOR Europe, Nov. 2011, by Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK […]

more info 10/24/2013View Related Articles
Bookmark and Share

FDAMA Section 114 and CER Master Slide Deck

Master slide deck from Tufts University which covers FDAMA Section 114 and CER […]

more info 10/24/2013View Related Articles
Bookmark and Share

Role of Government in CER

Presentation from Clifford Goodman, PhD delivered at the National Comparative Effectiveness Summit, Oct. 13, 2011 […]

more info 10/24/2013View Related Articles
Bookmark and Share

  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page

 

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

    No feed items found.

 
Syndicated Reports

Biotech R&D: a target-rich environment

Global Gene Therapy Report 2022-2031

ePrescribing Market – This is How Key Players are Dominating Global Industry

Health Economics and Outcomes Research (HEOR) Services Market to 2028

 
White Papers

Real World Evidence Solutions Global Market Report 2022

AI for Pharma and Biotech Market Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by Forecast 2026

Whitepaper – Engaging the End Prescriber: A Practical Guide to Working With Physicians

Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines

HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Webinars
    • Conferences
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists